190 related articles for article (PubMed ID: 19813275)
41. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
43. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
44. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Lorusso D; Ferrandina G; Greggi S; Gadducci A; Pignata S; Tateo S; Biamonte R; Manzione L; Di Vagno G; Ferrau' F; Scambia G;
Ann Oncol; 2003 Jul; 14(7):1086-93. PubMed ID: 12853351
[TBL] [Abstract][Full Text] [Related]
45. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
46. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Hussain AE; Blakley BW; Nicolas M; Balderston J
J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
[TBL] [Abstract][Full Text] [Related]
47. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
48. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
49. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J; Nannan Panday VR; Hoekman K; Rosing H; Huijskes RV; Verheijen RH; Beijnen JH; Vermorken JB
Am J Clin Oncol; 2001 Aug; 24(4):401-3. PubMed ID: 11474273
[TBL] [Abstract][Full Text] [Related]
50. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
51. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
52. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
53. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Planting AS; Catimel G; de Mulder PH; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken JB
Ann Oncol; 1999 Jun; 10(6):693-700. PubMed ID: 10442192
[TBL] [Abstract][Full Text] [Related]
54. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
[TBL] [Abstract][Full Text] [Related]
55. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Gómez HL; Samanéz C; Campana F; Neciosup SP; Vera L; Casanova L; Leon J; Flores C; de Mendoza FH; Casteñeda CA; Pinto JA; Vallejos CS
Hematol Oncol Stem Cell Ther; 2012; 5(3):152-7. PubMed ID: 23095791
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis.
Nijstad AL; van Eijkelenburg NKA; Kraal KCJM; Meijs MJM; de Kanter CTMM; Lilien MR; Huitema ADR
Cancer Chemother Pharmacol; 2020 Sep; 86(3):445-449. PubMed ID: 32816154
[TBL] [Abstract][Full Text] [Related]
57. Fibrolamellar hepatocellular carcinoma in children and adolescents.
Katzenstein HM; Krailo MD; Malogolowkin MH; Ortega JA; Qu W; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Newman K; Finegold MJ; Haas JE; Sensel MG; Castleberry RP; Bowman LC
Cancer; 2003 Apr; 97(8):2006-12. PubMed ID: 12673731
[TBL] [Abstract][Full Text] [Related]
58. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
59. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
60. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
